Abbonarsi

Clinical significance of lncRNA XIST expression in cholangiocarcinoma and its effect on cell migration and invasion - 28/06/24

Doi : 10.1016/j.clinre.2024.102398 
Chenxi Li a, #, Yifei Dong b, #, Yichuan Zhang c, , Caihong Wu d, e, f,
a Department of General Surgery, Wenling Hospital of Traditional Chinese Medicine, Wenling 317500, China 
b Department of Laboratory, The Eighth Hospital of Wuhan, Wuhan 430010, China 
c Minimally Invasive Endoscopy Center, Digestive Disease Center, The Affiliated Hospital of Panzhihua University, Panzhihua 617000, China 
d Department of Anesthesiology, The Second Xiangya Hospital of Central South University, Changsha 421001, China 
e Anesthesia Medical Research Center of Central South University, Changsha 421001, China 
f Department of Clinical Nursing, The Second Xiangya Hospital of Central South University, Changsha 421001, China 

⁎⁎Corresponding author at: Department of Anesthesiology, The Second Xiangya Hospital of Central South University; Anesthesia Medical Research Center of Central South University; Department of Clinical Nursing, The Second Xiangya Hospital of Central South University, No. 139, Renmin Middle Road, Furong District, Changsha 421001, China.Department of AnesthesiologyThe Second Xiangya Hospital of Central South UniversityAnesthesia Medical Research Center of Central South UniversityDepartment of Clinical NursingThe Second Xiangya Hospital of Central South UniversityNo. 139, Renmin Middle Road, Furong DistrictChangsha421001ChinaCorresponding author at: Minimally Invasive Endoscopy Center, Digestive Disease Center, The Affiliated Hospital of Panzhihua University, 27 Taoyuan Street, East District, Panzhihua 617000, China.Minimally Invasive Endoscopy CenterDigestive Disease CenterThe Affiliated Hospital of Panzhihua University27 Taoyuan Street, East DistrictPanzhihua617000China

Hightlights

XIST may serve as a prognostic biomarker for cholangiocarcinoma.
Overexpression of XIST inhibited tumor progression by targeting miR-126–3p.
XIST has a carcinogenic role in cholangiocarcinoma.

Il testo completo di questo articolo è disponibile in PDF.

Abstract

Background

Cholangiocarcinoma is a malignant tumor that occurs in the bile duct system, and the prognosis of patients is poor. Currently, research suggests that long non-coding RNAs (lncRNAs) in the treatment and prevention of cholangiocarcinoma. This study primarily focuses on the regulation and potential mechanism of the lncRNA XIST (XIST) in cholangiocarcinoma.

Methods

The levels of XIST and miR-126–3p in cholangiocarcinoma tissues and cells were detected using real-time quantitative polymerase chain reaction (RT-qPCR). Cell transfection status, including migration and invasion, was examined via the Transwell method. The relationship between XIST and miR-126–3p was observed by dual-luciferase gene reporter assay and verified by rescue assays. Additionally, the prognostic significance of XIST in cholangiocarcinoma was determined using Kaplan-Meier and multivariate Cox regression analyses.

Results

XIST expression was increased in cholangiocarcinoma, while miR-126–3p was decreased, in both tissues and cells. The successful construction of silencing XIST was found to inhibit the count of cell migration and invasion. XIST directly targeted miR-126–3p to regulate the progression of cholangiocarcinoma.

Conclusion

XIST sponging miR-126–3p inhibited the progression of cholangiocarcinoma and improved the prognosis for patients. This finding provides new insights and opportunities for future studies on cholangiocarcinoma prognostic biomarkers.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : lncRNA XIST, miR-126–3p, Cholangiocarcinoma, Prognostic biomarker


Mappa


© 2024  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 48 - N° 7

Articolo 102398- Agosto 2024 Ritorno al numero
Articolo precedente Articolo precedente
  • Visceral fat and clinical outcome in patients receiving first-line chemotherapy with bevacizumab for metastatic colorectal cancer
  • Nicolas Cazeneuve, Olivier Bouché, Julie Leger, Christophe Borg, Catherine Labbe-Devilliers, Olivier Lucidarme, Jean-Pierre Tasu, Sylvain Manfredi, Christophe Aubé, Hervé Trillaud, Philippe Manzoni, Claude Marcus, Eric Terrebonne, Jean-Yves Douillard, Romain Chautard, Sarah Lobet, Béatrice Scotto, Aurore Bleuzen, Thierry Lecomte
| Articolo seguente Articolo seguente
  • Validation of a novel BCM model for recurrence risk prediction after mucosectomy of colorectal lateral spreading tumors in a European cohort
  • Sofia Bragança, Ana Catarina Garcia, Gonçalo Alexandrino, Ana Maria Oliveira, David Horta, Luís Carvalho Lourenço, Mariana Nuno Costa

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.